Advanced Stage Is the Most Important Prognostic Factor for Survival in Patients with Systemic Acquired Immunodeficiency Syndrome-Related Non-Hodgkin's Lymphoma Treated with CHOP and Highly Active Antiretroviral Therapy
José‐Tomás Navarro(Universitat Autònoma de Barcelona), Evarist Feliú(Universitat Autònoma de Barcelona), Albert Oriol(Institut Català d'Oncologia), Fuensanta Millá, Blanca Xicoy(Hospital Universitari Germans Trias i Pujol), Josep‐María Ribera(Universitat Autònoma de Barcelona), Natàlia Lloveras, Guillem Sirera, José Luís Mate(Universitat Autònoma de Barcelona)
Cited by 10
Related Papers
Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study
|The Lancet Oncology|2014|1.3k
Teclistamab in Relapsed or Refractory Multiple Myeloma
|New England Journal of Medicine|2022|1.2k
Cilta-cel or Standard Care in Lenalidomide-Refractory Multiple Myeloma
|New England Journal of Medicine|2023|719